RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1
about
Gene, Stem Cell, and Alternative Therapies for SCA 1Precision medicine in spinocerebellar ataxias: treatment based on common mechanisms of diseaseSmall RNA Detection by in Situ Hybridization MethodsCurrent understanding of the role of microRNAs in spinocerebellar ataxiasOligonucleotide-based strategies to combat polyglutamine diseases.Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapyBroad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy.Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia.Assessing recovery from neurodegeneration in spinocerebellar ataxia 1: Comparison of in vivo magnetic resonance spectroscopy with motor testing, gene expression and histology.RNA interference-based therapy for spinocerebellar ataxia type 7 retinal degeneration.Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7.MiR-298 Counteracts Mutant Androgen Receptor Toxicity in Spinal and Bulbar Muscular Atrophy.RNAi prevents and reverses phenotypes induced by mutant human ataxin-1.Gene therapies for inherited retinal disorders.Toward stem cell-based phenotypic screens for neurodegenerative diseases.Allele-selective suppression of mutant genes in polyglutamine diseases.Epigenetic profiles in polyglutamine disorders.
P2860
Q26738497-33421877-78A3-4CE8-942A-6E3ECBC7BF06Q26764958-D32B1441-FE29-4835-8FBF-C1944109D0B4Q27011992-33F88331-7BFA-45BA-A4E5-82581057FABAQ27028008-EF4C743E-DF4C-4765-9E9A-E485AE013C5EQ33791247-0BE9B11C-388B-4985-AB12-79C9BD09D084Q34397572-EFD5EE1E-29A9-48A3-8B8D-D5F50B0F3E8DQ34498957-A33F31FB-A9B3-4D3A-8E61-D8991558CD01Q34499502-7A45C8C9-2CEC-4A6C-B44B-A47A8EC34410Q35070164-8BC21A84-8B3A-4485-B363-7E1006720E0BQ35156007-B3FD5CDA-470A-450B-B477-4BD933AEED9AQ35618581-6A0FD0EF-6638-4BC5-88A5-21764FF89CABQ36939759-290C2BBB-1717-45A4-87E1-0BFF03354705Q37423590-9FA908D5-F41F-44F6-84C6-6A1C5768D74AQ38221905-E248471C-1965-4406-B593-59BC7A0B9C8DQ38489289-5EB19268-AAC7-4741-9171-B633A1AC03D0Q38547027-59F05ABF-E292-439B-BDA3-2D6A0BDAC6F7Q49668183-D994DB58-E6EA-4705-BC44-D5D6FD099B90
P2860
RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1
@ast
RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1
@en
RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1
@nl
type
label
RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1
@ast
RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1
@en
RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1
@nl
prefLabel
RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1
@ast
RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1
@en
RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1
@nl
P2093
P2860
P1476
RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1
@en
P2093
Beverly L Davidson
James C Geoghegan
Kim A Lennox
Megan S Keiser
P2860
P356
10.1016/J.NBD.2013.04.003
P577
2013-04-10T00:00:00Z